newsfilter
← Latest News
GlobeNewswire·

Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress

  • Enlivex Ltd. (NASDAQ: ENLV) announced it will present two poster abstracts at the OARSI 2026 World Congress on Osteoarthritis in West Palm Beach, Florida, from April 23-26, 2026.
  • The presentations feature 3-month & 6-month clinical data from the Phase IIa trial (NCT06233474) of Allocetra™ for moderate-to-severe knee osteoarthritis.
  • Phase IIa results demonstrated clinically meaningful & statistically significant pain reduction & functional improvement in Allocetra™-treated patients versus placebo in idiopathic age-related osteoarthritis patients aged 60+ years.
  • Prof. Philip Conaghan, an international leader in osteoarthritis research, will present the clinical data.
  • A second presentation will cover pharmacological characterization data supporting Allocetra™'s novel immunomodulating mechanism of action.
  • Poster 405 (Abstract ID 4466183) details the Phase IIa trial results & will be presented on April 24 & 25, 2026, from 03:30 PM to 04:15 PM ET.
  • Poster 549 (Abstract ID 4466242) details the pharmacological characterization of Allocetra™ & will be presented on April 24 & 25, 2026, from 03:30 PM to 04:15 PM ET.
  • Enlivex operates a dual strategy combining clinical-stage immunotherapy development with a prediction markets treasury built around the RAIN token on the Rain protocol.